Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Activity of Sorafenib in Salivary Gland Cancer
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2023-10-19
- Target Recruit Count
- 37
- Registration Number
- NCT01703455
- Locations
- 🇮🇹
IRCCS Istituto Nazionale Tumori, Milano, Italy
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2016-03-04
- Target Recruit Count
- 13
- Registration Number
- NCT01683149
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 659
- Registration Number
- NCT01658878
- Locations
- 🇺🇸
Local Institution - 0002, Ann Arbor, Michigan, United States
🇺🇸Local Institution - 0008, Los Angeles, California, United States
🇺🇸Local Institution - 0048, Washington, District of Columbia, United States
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 24
- Registration Number
- NCT01640665
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 43
- Registration Number
- NCT01636908
- Locations
- 🇳🇱
VUMedical Center, Amsterdam, Netherlands
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01620216
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT01618253
- Locations
- 🇺🇸
Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States
Study of Curcumin, Vorinostat, and Sorafenib
- Conditions
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01608139
Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT01578109
- Locations
- 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 12
- Registration Number
- NCT01561833
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.